Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04252495
Other study ID # ID-080-109
Secondary ID 2019-003580-21
Status Completed
Phase Phase 1
First received
Last updated
Start date June 26, 2020
Est. completion date May 6, 2021

Study information

Verified date November 2022
Source Idorsia Pharmaceuticals Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a prospective, open-label, single-dose, Phase 1 study, to assess the effect of moderate hepatic impairment due to liver cirrhosis on the pharmacokinetics of aprocitentan (ACT-132577).


Recruitment information / eligibility

Status Completed
Enrollment 17
Est. completion date May 6, 2021
Est. primary completion date April 5, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 30 Years to 79 Years
Eligibility Inclusion Criteria: - Signed informed consent in a language understandable to the subject prior to any study-mandated procedure. - Women of childbearing potential (WoCBP) must have a negative serum pregnancy test at screening and a negative urine pregnancy test on Day -1 and must agree to use highly effective methods of contraception from screening up to 30 days after study treatment. - A Women of non-childbearing potential (WoNCBP) must meet one of the following criteria: - Previous bilateral salpingectomy, salpingo-oophorectomy or hysterectomy. - Premature ovarian failure confirmed by a specialist gynecologist. - Post-menopausal, defined as 12 consecutive months with amenorrhea prior to screening without alternative medical cause and confirmed with a follicle stimulating hormone test. - Body mass index of 18.0 to 35.0 kg/m2 (inclusive) at screening. - Normal renal function confirmed by a creatinine clearance at screening according to Cockcroft and Gault adjusted to age. - Additional principal inclusion criteria for subjects with moderate hepatic impairment (Group 1) - Moderate hepatic function impairment due to liver cirrhosis defined as a score of 7-9 (inclusive) according to the Child-Pugh classification. - Systolic blood pressure 95 to 160 mmHg, diastolic blood pressure 60 to 95 mmHg, and pulse rate 50 to 100 bpm (inclusive), measured on the same arm, after 5 minutes in the supine position at screening and on Day 1 pre-dose. - International normalized ratio equal or less than 2.5 at screening. - Stable concomitant medications for at least 3 weeks prior to screening and up to Day 1 and expected to be stable during the conduct of the study. - Additional principal inclusion criteria for healthy subjects (Group 2) - Healthy on the basis of medical history, physical examination, cardiovascular assessments, and clinical laboratory tests. Exclusion Criteria: - Pregnant or lactating women. - Previous exposure to aprocitentan and/or macitentan. - Known hypersensitivity to any excipients of the drug formulation. - Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol. - Any signs or symptoms of active, ongoing infection judged to be clinically relevant by the investigator (special attention should be given to COVID-19, e.g., fever, dry cough, dyspnea, sore throat, or fatigue). - Subjects must adhere to the clinical site's house rules, which include, amongst others, polymerase chain reaction testing for SARS-CoV-2 at screening and admission. - Legal incapacity or limited legal capacity at screening. - Additional exclusion criteria for subjects with moderate hepatic impairment (Group 1) - History or clinical evidence of any disease and/or existence of any surgical or medical condition, which might interfere with the absorption, distribution, metabolism, or excretion (ADME) of the study treatment except for those related to liver cirrhosis (appendectomy and herniotomy allowed, cholecystectomy not allowed). - Hepatic cancer, primary biliary cirrhosis, or any form of cholestatic disease. - Clinical evidence or suspected acute liver failure as judged by the investigator. - Encephalopathy grade greater than 2. - Severe ascites and/or pleural effusion. - Clinically relevant findings in clinical laboratory tests (hematology, coagulation, clinical chemistry, and urinalysis) at screening & on Day -1, except for those related to liver cirrhosis. - Additional exclusion criteria for healthy subjects (Group 2) - Clinically relevant findings on the physical examination at screening. - History or clinical evidence of any disease and/or existence of any surgical or medical condition, which might interfere with the absorption, distribution, metabolism, or excretion (ADME) of the study treatment (appendectomy and herniotomy allowed, cholecystectomy not allowed). - Clinically relevant findings in clinical laboratory tests (hematology, coagulation, clinical chemistry, and urinalysis) at screening & on Day -1. - Clinically relevant abnormalities on a 12-lead ECG, recorded after 5 min in the supine position at screening & on Day 1 pre-dose.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Aprocitentan
A single oral dose of 25 mg.

Locations

Country Name City State
Germany CRS Clinical Research Services Kiel GmbH Kiel
Poland Biokinetica S.A. Jozefow

Sponsors (1)

Lead Sponsor Collaborator
Idorsia Pharmaceuticals Ltd.

Countries where clinical trial is conducted

Germany,  Poland, 

Outcome

Type Measure Description Time frame Safety issue
Primary The maximum plasma concentration (Cmax) of aprocitentan Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 14.
Primary Area under the plasma concentration-time curves (AUC0-t) of aprocitentan Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 14.
Primary Area under the plasma concentration-time curve to infinity (AUC0 to inf) of aprocitentan Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 14.
Secondary Treatment-emergent Adverse Events From study treatment administration on Day 1 up to last assessment on End of Study (Day 15)
See also
  Status Clinical Trial Phase
Completed NCT05483998 - A Study to Evaluate Single and Multiple Doses of TLC-2716 in Healthy Participants Phase 1
Recruiting NCT02235012 - Cognitive Biases Under Ketamine N/A
Recruiting NCT02417714 - Prospective Evaluation of Next Generation CT Reconstruction (NextGenIR)
Completed NCT05088343 - Effect of Hetrombopag on the Pharmacokinetics of Rosuvastatin in Healthy Subjects Phase 1
Completed NCT04418973 - Analysis of Breath Volatile Organic Compounds After Dyspnea Induced in the Healthy Subject. N/A
Not yet recruiting NCT06248801 - Vildagliptin and Metformin Tablets 50/1000 mg Relative to GALVUS MET (50mg/1000 mg) Tablets Phase 1
Terminated NCT04068259 - Single Ascending Dose Study of PBI-4547 in Healthy Subjects Phase 1
Completed NCT03279302 - Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects Phase 1
Not yet recruiting NCT06233162 - Febuxostat 80 mg Tablets Relative to Feburic® 80 mg Tablets Phase 1
Recruiting NCT04159844 - Evaluation of the Stiffness and Pressure Applied on the Lower Leg by a New Compression Bandage on Healthy Subjects N/A
Completed NCT06137911 - Evaluation of Safety, Tolerability & Pharmacokinetics of JYP0061 in Healthy Adults. Phase 1
Completed NCT04849286 - Measurement of HTL0016878 in Cerebrospinal Fluid Phase 1
Not yet recruiting NCT06233227 - Dutasteride Soft Capsule 0.5 mg Relative to Avodart 0.5 mg Soft Capsule Phase 1
Completed NCT04096157 - A Study to Assess Isavuconazole Following a Single Dose of Isavuconazonium Sulfate Intravenous Solution Via Nasogastric (NG) Tube Compared to a Single Dose of Oral Capsules Under Fasting Conditions in Healthy Participants Phase 1
Completed NCT01200368 - Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants Phase 3
Recruiting NCT05805033 - Peri-Implant Soft Tissue Integration in Humans: Influence of Material N/A
Completed NCT04027803 - Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris® Phase 1
Recruiting NCT03467880 - Multicenter Study of Impulse Oscillometry in Chinese N/A
Completed NCT02903095 - Single Ascending Dose Study of TD-1439 in Healthy Subjects Phase 1
Active, not recruiting NCT02341508 - A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers Phase 1